{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:35:01Z","timestamp":1793648101248,"version":"4.5.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>BET inhibitors have been tested in several clinical trials where, despite encouraging preclinical results, substantial clinical benefit in monotherapy remains limited. This work illustrates the translational challenges and reports new data around the novel BET inhibitor, BI 894999. At clinically achievable concentrations, mechanistic studies were carried out to study pathway modulation and rational drug combinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>BRD-NUT fusions are oncogenic drivers in NUT carcinoma (NC). The effects of BI 894999 on proliferation, chromatin binding and pathway modulation were studied in NC in vitro. These studies were complemented by efficacy studies either as a single agent or in combination with the clinical p300\/CBP inhibitor CCS1477.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on the modelling of preclinical and clinical data, we proposed and implemented a new clinical scheduling regimen. This led to plasma levels sufficient to fully dislodge BRD-NUT from chromatin and to sustained and pronounced pharmacodynamic (PD) modulation of HEXIM1 and HIST2H2BF. Platelet counts in patient blood samples were improved compared to previous schedules. Rational combination studies of BI 894999 performed at clinically meaningful concentrations led to tumour regressions in all NC xenograft models tested.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>BI 894999 holds significant potential as a combination drug and CCS1477 p300\/CBP inhibitor is a promising partner for future clinical trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-01815-5","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T20:03:20Z","timestamp":1650485000000},"page":"577-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-964X","authenticated-orcid":false,"given":"Ulrike","family":"Tontsch-Grunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula-Elena","family":"Traexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanny","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristell","family":"Marzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8170-1893","authenticated-orcid":false,"given":"Harald","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Solca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"1815_CR1","doi-asserted-by":"publisher","first-page":"36609","DOI":"10.1074\/jbc.M112.410746","volume":"287","author":"K Bartholomeeusen","year":"2012","unstructured":"Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem. 2012;287:36609\u201316. https:\/\/doi.org\/10.1074\/jbc.M112.410746.","journal-title":"J Biol Chem"},{"key":"1815_CR2","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.cell.2013.10.056","volume":"155","author":"W Liu","year":"2013","unstructured":"Liu W, Ma Q, Wong K, Li W, Ohgi K, Zhang J, et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell. 2013;155:1581\u201395. https:\/\/doi.org\/10.1016\/j.cell.2013.10.056.","journal-title":"Cell."},{"key":"1815_CR3","doi-asserted-by":"publisher","first-page":"232870","DOI":"10.1155\/2014\/232870","volume":"2014","author":"R Chen","year":"2014","unstructured":"Chen R, Yik JH, Lew QJ, Chao SH. Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. Biomed Res Int. 2014;2014:232870 https:\/\/doi.org\/10.1155\/2014\/232870.","journal-title":"Biomed Res Int"},{"key":"1815_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54:728\u201336. https:\/\/doi.org\/10.1016\/j.molcel.2014.05.016.","journal-title":"Mol Cell"},{"key":"1815_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2217\/epi.14.91","volume":"7","author":"M Jung","year":"2015","unstructured":"Jung M, Gelato KA, Fern\u00e1ndez-Montalv\u00e1n A, Siegel S, Haendler B, Targeting BET. bromodomains for cancer treatment. Epigenomics. 2015;7:487\u2013501. https:\/\/doi.org\/10.2217\/epi.14.91.","journal-title":"Epigenomics."},{"key":"1815_CR6","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","volume":"27","author":"CA French","year":"2008","unstructured":"French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27:2237\u201342.\u00a0https:\/\/doi.org\/10.1038\/sj.onc.1210852.","journal-title":"Oncogene"},{"key":"1815_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.acr.2016.04.001","volume":"131","author":"CA French","year":"2016","unstructured":"French CA. Small-molecule targeting of BET proteins in cancer. Adv Cancer Res. 2016;131:21\u201358. https:\/\/doi.org\/10.1016\/bs.acr.2016.04.001.","journal-title":"Adv Cancer Res"},{"key":"1815_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/pin.12727","volume":"68","author":"CA French","year":"2018","unstructured":"French CA. NUT carcinoma: clinicopathologic features, pathogenesis, and treatment. Pathol Int. 2018;68:583\u201395. https:\/\/doi.org\/10.1111\/pin.12727.","journal-title":"Pathol Int"},{"key":"1815_CR9","doi-asserted-by":"publisher","first-page":"pkz094","DOI":"10.1093\/jncics\/pkz094.","volume":"4","author":"NG Chau","year":"2019","unstructured":"Chau NG, Ma C, Danga K, Al-Sayegh H, Nardi V, Barrette R, et al. An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2019;4:pkz094 https:\/\/doi.org\/10.1093\/jncics\/pkz094.","journal-title":"JNCI Cancer Spectr"},{"key":"1815_CR10","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","volume":"33","author":"H Haack","year":"2009","unstructured":"Haack H, Johnson LA, Fry CJ, Crosby K, Polakiewicz RD, Stelow EB, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009;33:984\u201391. https:\/\/doi.org\/10.1097\/PAS.0b013e318198d666.","journal-title":"Am J Surg Pathol"},{"key":"1815_CR11","doi-asserted-by":"publisher","first-page":"102826","DOI":"10.1016\/j.critrevonc.2019.102826","volume":"144","author":"M Salati","year":"2019","unstructured":"Salati M, Baldessari C, Bonetti LR, Messina C, Merz V, Cerbelli B, et al. NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity. Crit Rev Oncol Hematol. 2019;144:102826 https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102826.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1815_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","volume":"6","author":"A Stathis","year":"2016","unstructured":"Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015\/MK-8628. Cancer Discov. 2016;6:492\u2013500. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1335.","journal-title":"Cancer Discov"},{"key":"1815_CR13","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292.","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumours. J Clin Oncol. 2018;36:3007\u201314. https:\/\/doi.org\/10.1200\/JCO.2018.78.2292.","journal-title":"J Clin Oncol"},{"key":"1815_CR14","doi-asserted-by":"publisher","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093.","volume":"4","author":"SA Piha-Paul","year":"2019","unstructured":"Piha-Paul SA, Hann CL, French CA, Cousin S, Bra\u00f1a I, Cassier PA, et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumours. JNCI Cancer Spectr. 2019;4:pkz093 https:\/\/doi.org\/10.1093\/jncics\/pkz093.","journal-title":"JNCI Cancer Spectr"},{"key":"1815_CR15","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41416-020-01180-1.","volume":"124","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, LoRusso P, Dowlati A, Do KT, Jacobson CA, Vaishampayan U, et al. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021;124:744\u201353. https:\/\/doi.org\/10.1038\/s41416-020-01180-1.","journal-title":"Br J Cancer"},{"key":"1815_CR16","doi-asserted-by":"publisher","first-page":"E159","DOI":"10.1073\/pnas.1102140108.","volume":"108","author":"JM Lamonica","year":"2011","unstructured":"Lamonica JM, Deng W, Kadauke S, Campbell AE, Gamsjaeger R, Wang H, et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. PNAS. 2011;108:E159\u2013E168. https:\/\/doi.org\/10.1073\/pnas.1102140108.","journal-title":"PNAS"},{"key":"1815_CR17","doi-asserted-by":"publisher","unstructured":"Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, et al. Targeting p300\/CBP axis in lethal prostate cancer. Cancer Discov. 2021. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0751.","DOI":"10.1158\/2159-8290.CD-20-0751"},{"key":"1815_CR18","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1038\/emboj.2010.176.","volume":"29","author":"N Reynoird","year":"2010","unstructured":"Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, et al. Oncogenesis by sequestration of CBP\/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010;29:2943\u201352. https:\/\/doi.org\/10.1038\/emboj.2010.176.","journal-title":"EMBO J"},{"key":"1815_CR19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1101\/gad.267583.115.","volume":"29","author":"AA Alekseyenko","year":"2015","unstructured":"Alekseyenko AA, Walsh EM, Wang X, Grayson AR, Hsi PT, Kharchenko PV, et al. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev. 2015;29:1507\u201323. https:\/\/doi.org\/10.1101\/gad.267583.115.","journal-title":"Genes Dev"},{"key":"1815_CR20","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1038\/s41388-020-1301-9.","volume":"39","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zegar T, Lucas A, Morrison-Smith C, Knox T, French CA, et al. Therapeutic targeting of p300\/CBP HAT domain for the treatment of NUT midline carcinoma. Oncogene. 2020;39:4770\u20139. https:\/\/doi.org\/10.1038\/s41388-020-1301-9.","journal-title":"Oncogene."},{"key":"1815_CR21","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-20-0087.","volume":"19","author":"CD Morrison-Smith","year":"2020","unstructured":"Morrison-Smith CD, Knox TM, Filic I, Soroko KM, Eschle BK, Wilkens MK, et al. Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734. Mol Cancer Ther. 2020;19:1406\u201314. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0087.","journal-title":"Mol Cancer Ther"},{"key":"1815_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/jpet.114.221150.","volume":"352","author":"D Rudolph","year":"2015","unstructured":"Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, et al. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia. J Pharmacol Exp Ther. 2015;352:579\u201389. https:\/\/doi.org\/10.1124\/jpet.114.221150.","journal-title":"J Pharmacol Exp Ther"},{"key":"1815_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2018.02.018.","volume":"421","author":"U Tontsch-Grunt","year":"2018","unstructured":"Tontsch-Grunt U, Rudolph D, Waizenegger I, Baum A, Gerlach D, Engelhardt H, et al. Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. Cancer Lett. 2018;421:112\u201320. https:\/\/doi.org\/10.1016\/j.canlet.2018.02.018.","journal-title":"Cancer Lett"},{"key":"1815_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol. 1939;26:585\u2013615.","journal-title":"Ann Appl Biol"},{"key":"1815_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142.","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11:142\u201357. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0142.","journal-title":"Cancer Discov"},{"key":"1815_CR26","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/bioinformatics\/btz647.","volume":"36","author":"M Canouil","year":"2020","unstructured":"Canouil M, Bouland GA, Bonnefond A, Froguel P, \u2018t Hart LM, Slieker RC. NACHO: an R package for quality control of NanoString nCounter data. Bioinformatics. 2020;36:970\u20131. https:\/\/doi.org\/10.1093\/bioinformatics\/btz647.","journal-title":"Bioinformatics"},{"key":"1815_CR27","doi-asserted-by":"publisher","unstructured":"Wickham H. ggplot2. 2011; Wiley Interdiscip Rev Comput Stat. 2011. https:\/\/doi.org\/10.1002\/wics.147.","DOI":"10.1002\/wics.147"},{"key":"1815_CR28","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/s41388-018-0150-2.","volume":"37","author":"D Gerlach","year":"2018","unstructured":"Gerlach D, Tontsch-Grunt U, Baum A, Popow J, Scharn D, Hofmann MH, et al. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene. 2018;37:2687\u2013701. https:\/\/doi.org\/10.1038\/s41388-018-0150-2.","journal-title":"Oncogene."},{"key":"1815_CR29","doi-asserted-by":"publisher","first-page":"Abstract nr 519","DOI":"10.1158\/1538-7445.AM2019-5194","volume":"79","author":"F Savarese","year":"2019","unstructured":"Savarese F, Gerlach D, Koller L, Straubinger S, Tr\u00e4xler PE, Kaya O, et al. Epigenomic and transcriptional profiling of CRC cell lines with distinct response patterns to the BET inhibitor BI 894999. Cancer Res. 2019;79:Abstract nr 5194.","journal-title":"Cancer Res"},{"key":"1815_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504.","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith W, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067\u201373. https:\/\/doi.org\/10.1038\/nature09504.","journal-title":"Nature"},{"key":"1815_CR31","doi-asserted-by":"publisher","first-page":"Abstract nr B79","DOI":"10.1158\/1535-7163.TARG-15-B79","volume":"14","author":"U Tontsch-Grunt","year":"2015","unstructured":"Tontsch-Grunt U, Savarese F, Gerlach D, Gianni D, Baum A, Scharn D, et al. BI 894999, a novel BET inhibitor: Treatment of hematological malignancies by repression of super-enhancer driven oncogenes. Mol Cancer Ther. 2015;14:Abstract nr B79.","journal-title":"Mol Cancer Ther"},{"key":"1815_CR32","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/1535-7163.MCT-16-0475.","volume":"16","author":"X Lin","year":"2017","unstructured":"Lin X, Huang X, Uziel T, Hessler P, Albert DH, Roberts-Rapp LA, et al. HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumours and surrogate tissues. Mol Cancer Ther. 2017;16:388\u201396. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0475.","journal-title":"Mol Cancer Ther"},{"key":"1815_CR33","doi-asserted-by":"publisher","first-page":"#2504","DOI":"10.1200\/JCO.2017.35.15_suppl.2504","volume":"35","author":"PG Aftimos","year":"2017","unstructured":"Aftimos PG, Bechter O, Awada A, Jungels C, Dumez H, Huyvaert N, et al. Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumours. J Clin Oncol. 2017;35:#2504.","journal-title":"J Clin Oncol"},{"key":"1815_CR34","doi-asserted-by":"publisher","first-page":"107479.","DOI":"10.1016\/j.pharmthera.2020.107479.","volume":"208","author":"O Bechter","year":"2020","unstructured":"Bechter O, Sch\u00f6ffski P. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumours. Pharmacol Ther. 2020;208:107479. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107479.","journal-title":"Pharmacol Ther"},{"key":"1815_CR35","doi-asserted-by":"publisher","unstructured":"Roboz GJ, Desai P, Lee S, Ritchie EK, Winer ES, DeMario M, et al. A dose escalation study of RO6870810\/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2021. https:\/\/doi.org\/10.1080\/10428194.2021.1881509.","DOI":"10.1080\/10428194.2021.1881509"},{"key":"1815_CR36","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/cncr.33590.","volume":"127","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, et al. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed\/refractory acute myeloid leukemia. Cancer. 2021;127:2943\u201353. https:\/\/doi.org\/10.1002\/cncr.33590.","journal-title":"Cancer"},{"key":"1815_CR37","doi-asserted-by":"publisher","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumours: a systematic study of clinical trials. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2020.621093","DOI":"10.3389\/fphar.2020.621093"},{"key":"1815_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898.","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015;525:543\u20137. https:\/\/doi.org\/10.1038\/nature14898.","journal-title":"Nature"},{"key":"1815_CR39","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/s41388-020-01625-0.","volume":"40","author":"KP Eagen","year":"2021","unstructured":"Eagen KP, French CA. Supercharging BRD4 with NUT in carcinoma. Oncogene. 2021;40:1396\u2013408. https:\/\/doi.org\/10.1038\/s41388-020-01625-0.","journal-title":"Oncogene"},{"key":"1815_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004.","volume":"19","author":"G Andrieu","year":"2016","unstructured":"Andrieu G, Belkina AC, Denis GV. Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today Technol. 2016;19:45\u201350. https:\/\/doi.org\/10.1016\/j.ddtec.2016.06.004.","journal-title":"Drug Discov Today Technol"},{"key":"1815_CR41","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41416-020-01079-x.","volume":"123","author":"MM Mita","year":"2020","unstructured":"Mita MM, Mita AC. Bromodomain inhibitors a decade later: a promise unfulfilled? Br J Cancer. 2020;123:1713\u20134. https:\/\/doi.org\/10.1038\/s41416-020-01079-x.","journal-title":"Br J Cancer"},{"key":"1815_CR42","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0.","volume":"124","author":"T Shorstova","year":"2021","unstructured":"Shorstova T, Foulkes WD, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer. 2021;124:1478\u201390. https:\/\/doi.org\/10.1038\/s41416-021-01321-0.","journal-title":"Br J Cancer"},{"key":"1815_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605.","volume":"8","author":"A Stathis","year":"2018","unstructured":"Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8:24\u201336. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0605.","journal-title":"Cancer Discov"},{"key":"1815_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drudis.2017.09.011.","volume":"23","author":"M Ramadoss","year":"2018","unstructured":"Ramadoss M, Mahadevan V. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discov Today. 2018;23:76\u201389. https:\/\/doi.org\/10.1016\/j.drudis.2017.09.011.","journal-title":"Drug Discov Today"},{"key":"1815_CR45","doi-asserted-by":"publisher","first-page":"pkz092","DOI":"10.1093\/jncics\/pkz092.","volume":"4","author":"P Martin-Romano","year":"2019","unstructured":"Martin-Romano P, Baldini C, Postel-Vinay S. How much can we bet on activity of BET inhibitors beyond NUT-midline carcinoma? JNCI Cancer Spectr. 2019;4:pkz092 https:\/\/doi.org\/10.1093\/jncics\/pkz092.","journal-title":"JNCI Cancer Spectr"},{"key":"1815_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4.","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumours\u2014past lessons and future promise. Nat Rev Clin Oncol. 2020;17:91\u2013107. https:\/\/doi.org\/10.1038\/s41571-019-0267-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"1815_CR47","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027.","volume":"78","author":"S Shu","year":"2020","unstructured":"Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanovi\u0107 B, et al. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer. Mol Cell. 2020;78:1096\u2013.e8. https:\/\/doi.org\/10.1016\/j.molcel.2020.04.027.","journal-title":"Mol Cell"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01815-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T23:21:47Z","timestamp":1659482507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01815-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8,1]]}},"alternative-id":["1815"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01815-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are full-time employees of Boehringer Ingelheim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal studies were done in an AAALAC accredited facility and handled according to the institutional, governmental and European Union guidelines (Austrian Animal Protection Laws, GV-SOLAS and FELASA guidelines). Animal studies were approved by the internal ethics committee and the local governmental committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}